The global epilepsy drugs market size is expected to reach USD 15.35 billion by 2030, registering a CAGR of 5.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.
Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.
Epilepsy Drugs Market Report Highlights
- Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).
- The third generation anti-epileptics segment accounted for the largest revenue share of around 39.3% in 2022. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
- North America dominated the market with the largest revenue share of around 45% in 2022. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.
- Asia Pacific is estimated to expand at the highest CAGR of 6.3% over the forecast period. The presence of favorable government initiatives such as the Intersectoral Global Action Plan on Epilepsy, Global Campaign Against Epilepsy, and others, as well as the launch of new-generation anti-epileptic drugs are the drivers expected to propel the growth of this market in the region.
Epilepsy Drugs Market Segmentation
Grand View Research has segmented the global epilepsy drugs market on the basis of product, and region:
Epilepsy Drugs Product Outlook (Revenue, USD Million, 2018 - 2030)
- First Generation Anti-epileptics
- Second Generation Anti-epileptics
- Third Generation Anti-epileptics
Epilepsy Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Norway
- Denmark
- Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
- Kuwait
Order a free sample PDF of the Epilepsy Drugs Market Intelligence Study, published by Grand View Research.